|By Business Wire||
|March 14, 2014 08:01 AM EDT||
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that its second NCE (new chemical entity) initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 (COX-2) and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1.
Dr. Robert Clark, director of cheminformatics sciences for Simulations Plus, said: “We’re very pleased to report that our second NCE project has again demonstrated that our ADMET Design Suite™ (ADMET Predictor™, MedChem Studio™, and MedChem Designer™, supplemented by GastroPlus™ simulations) provides tools that can rapidly and inexpensively generate new lead molecules with affinity for selected targets. This project was more challenging than the malaria NCE project we completed two years ago because this time our goal was to inhibit two targets with a single molecule while also providing good ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. Southern Research Institute in Birmingham, Alabama, performed the chemical synthesis and Cerep in Redmond, Washington, performed the COX-2 and COX-1 assays.”
Dr. Michael Lawless, team leader for cheminformatics studies at Simulations Plus, added: “The only COX-2 inhibitor remaining on the U.S. market is Celebrex® (celecoxib), after Vioxx® (rofecoxib) and others were withdrawn for cardiotoxicity side effects. Research after the Vioxx withdrawal indicated that to avoid cardiotoxicity when inhibiting COX-2, it is important to also inhibit COX-1 but to a lesser extent. Needless to say, we’re delighted that we were able to hit two targets with three of four molecules, and one of them is potent as well as having the desired property of higher affinity for COX-2 than for COX-1. The fact that these molecules were designed using only our own software suite is a testament to the capabilities provided by these powerful programs.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Once again we stuck our necks out and announced prior to synthesis that we were going to contract with a company to synthesize several molecules of our own design and have them tested to see if we were successful. In just a few months, and for a mere fraction of the normal cost required to design new lead molecules to hit one target, we were able to design single molecules that each hit two different targets. This process might take years using traditional methodologies. We are not aware of any other software company that has applied its tools in this way - to take the risk of designing new molecules, having them made, then having them tested, while openly announcing ahead of time and providing results as soon as they were available. There is a chance, although it is probably remote, that we might be able to license one or more of these molecules to a company that could take them forward into further structural refinements and development. However, our goal is not to become a drug company, but to show that our software tools provide very powerful capabilities that can dramatically reduce the time and cost to generate good lead molecules for a wide variety of targets. We plan to present our results at upcoming scientific meetings, to customers at on-site visits, and ultimately, to submit a publication to one of the peer-reviewed scientific journals that cover this area of science.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
Follow Us on Twitter
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, continued success with testing our new molecules to inhibit COX-2 and COX-1 enzymes and for other properties necessary for molecules to become drugs, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 28, 2016 03:30 AM EDT Reads: 2,323
Aug. 28, 2016 02:00 AM EDT Reads: 1,761
Aug. 28, 2016 01:45 AM EDT Reads: 2,140
Aug. 28, 2016 01:30 AM EDT Reads: 2,069
Aug. 28, 2016 01:00 AM EDT Reads: 2,960
Aug. 28, 2016 12:15 AM EDT Reads: 1,819
Aug. 27, 2016 11:00 PM EDT Reads: 3,994
Aug. 27, 2016 08:45 PM EDT Reads: 2,342
Aug. 27, 2016 08:45 PM EDT Reads: 1,774
Aug. 27, 2016 06:15 PM EDT Reads: 737
Aug. 27, 2016 06:00 PM EDT Reads: 3,093
Aug. 27, 2016 06:00 PM EDT Reads: 731
Aug. 27, 2016 05:15 PM EDT Reads: 1,580
Aug. 27, 2016 05:00 PM EDT Reads: 1,884
Aug. 27, 2016 04:45 PM EDT Reads: 1,636